Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Open Access
- 15 March 2022
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-7
Abstract
Background. Transarterial infusion (TAI) chemotherapy with the FOLFOX regimen has shown good efficacy and safety in the treatment of hepatocellular carcinoma (HCC). However, it has not been reported in intrahepatic cholangiocarcinoma (ICC). Methods. The data of consecutive patients with unresectable ICC who underwent TAI with the FOLFOX regimen from November 2016 to September 2019 were retrospectively analyzed. Treatment effectiveness and safety were evaluated and compared using the KaplanMeier method, log-rank test, Cox regression models, and χ2 test. Results. Twenty-nine patients were included in the study. The median overall survival (OS) was 16.2 months (95 CI, 13.019.4). The median progression-free survival (PFS) was 8.7 months (95 CI, 6.211.1). Twenty-seven patients were included in the efficacy analysis. There were 0, 10, 13, and 4 patients with CR, PR, SD, and PD, respectively, based on mRECIST criteria. The ORR was 37.0, and the DCR was 85.2. There were 27 patients (93.1) who experienced grade 1-2 AEs, while only 1 patient experienced grade 3 AEs. Conclusion. TAI with the FOLFOX regimen could be an effective and safe treatment for unresectable ICC.Keywords
Funding Information
- National Natural Science Foundation of China (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
- Natural Science Foundation of Guangdong Province (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
- Science and Technology Planning Project of Guangdong Province (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
- Medical Scientific Research Foundation of Guangdong Province (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
- Science and Technology Planning Project of Guangzhou (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
- Sun Yat-sen University Cancer Center (82172579, 81871985, 2018A0303130098, 2017A030310203, 2017A020215112, A2017477, 201903010017, 201904010479, 308-2015-014)
This publication has 15 references indexed in Scilit:
- Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safetyCancer Communications, 2018
- Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinomaJournal of Hepatology, 2018
- Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized studyChinese Journal of Cancer, 2017
- Radioembolization for the treatment of hepatocellular carcinomaClinical and Molecular Hepatology, 2017
- Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?HepatoBiliary Surgery and Nutrition, 2017
- Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patientsCancer, 2016
- The Global Burden of Cancer 2013JAMA Oncology, 2015
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- TACE versus TAE as therapy for hepatocellular carcinomaExpert Review of Anticancer Therapy, 2008
- Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?Journal of Hepatology, 2004